Education
About Us
Working with TipRanks
Follow Us
ROSC - ETF AI Analysis
Top Page
Hartford Multifactor Small Cap ETF (ROSC)
Rating:70Outperform
Price Target:―
Positive Factors
Broad Sector Diversification
The fund spreads its investments across many sectors, which can help reduce the impact if any one industry struggles.
Several Strong Top Holdings
A number of the largest positions, such as Amkor, Argan, and Dillard’s, have shown strong recent performance, supporting the ETF’s overall returns.
Solid Recent Performance Trend
The ETF has delivered steady gains over the past month and quarter, indicating positive recent momentum in its small-cap strategy.
Negative Factors
Higher Expense Ratio for a Small-Cap ETF
The fund’s expense ratio is on the higher side compared with many broad market ETFs, which slightly reduces net returns over time.
Concentrated U.S.-Only Exposure
With almost all assets invested in U.S. companies, the ETF offers little geographic diversification and is heavily tied to the U.S. economy.
Mixed Performance Among Top Holdings
Some key positions, including Macy’s, PTC Therapeutics, and Indivior, have shown weak recent performance, which can drag on the fund if this continues.
ROSC vs. SPDR S&P 500 ETF (SPY)
AUM51.82M
RegionNorth America
Expense Ratio0.34%
Beta0.84
IssuerHartford
Inception DateMar 24, 2015
Dividend Yield1.96%
Asset ClassEquity
Index TrackedHartford Multifactor Small Cap Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,877
30 Day Avg. Volume6,351
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
58.34Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering304
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ROSC Summary
Hartford Multifactor Small Cap ETF (ROSC) tracks the Hartford Multifactor Small Cap Index and invests in many smaller U.S. companies across different industries, including health care, consumer, financials, and technology. It uses a rules-based approach to pick stocks, aiming for a mix of value, quality, and momentum. Well-known names in the fund include Macy’s and Dillard’s. Someone might invest in ROSC for growth potential and diversification, since small companies can grow faster than large ones. A key risk is that small-cap stocks can be more volatile and can go up and down more sharply than the overall market.
How much will it cost me?The Hartford Multifactor Small Cap ETF (ROSC) has an expense ratio of 0.34%, which means you’ll pay $3.40 per year for every $1,000 invested. This is slightly higher than average for ETFs because it uses an actively managed multifactor strategy to select stocks, aiming to enhance returns and reduce risk. It’s a good option if you’re looking for a strategic approach to small-cap investing.
What would affect this ETF?The Hartford Multifactor Small Cap ETF (ROSC) could benefit from economic growth and innovation in sectors like Health Care and Technology, which are significant parts of its portfolio. However, it may face challenges from rising interest rates or economic slowdowns, which can disproportionately impact small-cap companies and consumer-focused sectors like Consumer Cyclical. Additionally, changes in U.S. regulations or trade policies could affect the ETF's performance due to its focus on U.S. small-cap stocks.
ROSC Top 10 Holdings
ROSC’s story is all about U.S. small caps quietly pulling their weight across a mix of sectors. Industrial names like Argan and Rush Enterprises are rising stars, giving the fund a solid boost, while National Healthcare adds steady health care strength. On the consumer side, Macy’s and Dillard’s are helping rather than hurting, reflecting a surprisingly resilient retail backdrop. The main drag comes from PTC Therapeutics and, to a lesser extent, Indivior, showing that small-cap health care can be a bit of a roller coaster in an otherwise broadly diversified lineup.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Argan | 1.39% | $718.67K | $5.97B | 270.01% | 73 Outperform | |
| HNI | 1.25% | $644.78K | $3.03B | -5.17% | 74 Outperform | |
| Macy's | 1.22% | $632.41K | $5.10B | 45.16% | 74 Outperform | |
| Garrett Motion | 1.21% | $624.27K | $3.58B | 104.00% | 71 Outperform | |
| National Healthcare | 1.19% | $618.04K | $2.61B | 78.95% | 74 Outperform | |
| PTC Therapeutics | 1.13% | $584.01K | $5.24B | 19.94% | 72 Outperform | |
| Frequency Electronics | 1.12% | $581.41K | $519.29M | 264.52% | 76 Outperform | |
| Supernus Pharmaceuticals | 1.12% | $580.92K | $3.12B | 70.55% | 55 Neutral | |
| Amkor | 1.11% | $574.92K | $11.02B | 123.36% | 69 Neutral | |
| Dillard's | 1.08% | $560.91K | $9.69B | 72.15% | 76 Outperform |
ROSC Technical Analysis
Neutral
―
Price Trends
49.49
Positive
47.44
Positive
45.03
Positive
Market Momentum
0.21
Positive
45.98
Neutral
37.12
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ROSC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 50.63, equal to the 50-day MA of 49.49, and equal to the 200-day MA of 45.03, indicating a neutral trend. The MACD of 0.21 indicates Positive momentum. The RSI at 45.98 is Neutral, neither overbought nor oversold. The STOCH value of 37.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ROSC.
ROSC Peer Comparison
Comparison Results
Performance Comparison
ROSC
Hartford Multifactor Small Cap ETF
49.72
9.49
23.59%
AFSM
First Trust Active Factor Small Cap ETF
―
―
―
BKSE
BNY Mellon US Small Cap Core Equity ETF
―
―
―
STXK
Strive 2000 ETF
―
―
―
SYZ
Lazard US Systematic Small Cap Equity ETF
―
―
―
FLQS
Franklin LibertyQ U.S. Small Cap Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents